Bishoy Morris Faltas

Bishoy Morris Faltas

Auto-generated profile, based on publicly available information

Bishoy Morris Faltas

Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CPChantal Pauli
Chantal Pauli
BHBenjamin D. Hopkins
Benjamin D. Hopkins
DPDavide Prandi
Davide Prandi
RSReid Shaw
Reid Shaw
TFTarcisio Fedrizzi
Tarcisio Fedrizzi
MRMark A. Rubin
Mark A. Rubin
Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the development of a robust precision cancer care platform that integrates whole-exome sequencing with a living biobank that enables high-throughput drug screens on patient-derived tumor organoids. To date, 56 tumor-derived organoid cultures and 19 patient-derived xenograft (PDX) models have been established from the 769 patients enrolled in an Institutional Review Board–approved clinical trial. Because genomics alone was insufficient to identify therapeutic options for the majority of patients with advanced disease, we used high-throughput drug screening to discover effective treatment strategies. Analysis of tumor-derived cells from four cases, two uterine malignancies and two colon cancers, identified effective drugs and drug combinations that were subsequently validated using 3-D cultures and PDX models. This platform thereby promotes the discovery of novel therapeutic approaches that can be assessed in clinical trials and provides personalized therapeutic options for individual patients where standard clinical options have been exhausted. Significance: Integration of genomic data with drug screening from personalized in vitro and in vivo cancer models guides precision cancer care and fuels next-generation research. Cancer Discov; 7(5); 462–77. ©2017 AACR. See related commentary by Picco and Garnett, p. 456. This article is highlighted in the In This Issue feature, p. 443

17 October 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BFBishoy M Faltas
Bishoy M Faltas
DPDavide Prandi
Davide Prandi
STScott T Tagawa
Scott T Tagawa
AMAna M Molina
Ana M Molina
DNDavid M Nanus
David M Nanus
MRMark A Rubin
Mark A Rubin

1 July 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
HBHimisha Beltran
Himisha Beltran
KEKenneth Eng
Kenneth Eng
JMJuan Miguel Mosquera
Juan Miguel Mosquera
Alexandros SigarasAlexandros Sigaras
Alexandros Sigaras
ARAlessandro Romanel
Alessandro Romanel
MRMark A. Rubin
Mark A. Rubin
High-throughput next-generation sequencing has provided enormous insight into the genomic landscape of several tumor types, illuminating molecularly defined tumor subtypes, identifying new druggable targets, and providing insights into the heterogeneity of many tumors.1 Metastatic tumors often undergo genomic evolution during progression and resistance, and therefore genomic drivers may not always be evident in the primary tumor. Furthermore, no specific guidelines exist to help clinicians interpret and contextualize individual patients’ genomic information when making therapeutic decisions. Herein, we describe an evidence-based precision medicine trial for patients with metastatic or treatment-resistant disease using a whole-exome sequencing (WES) clinical test called EXaCT-1, developed and validated by our group. Unique aspects include analysis of more than 21 000 genes of the cancer exome rather than a targeted hot-spot gene approach, complete disclosure of results through a WES clinical report, incorporation of metastatic and serial biopsies, use of fresh/frozen and formalin-fixed tissue, and development of patient-derived organoids and xenografts for co-clinical trials. Integral to the study are a comprehensive computational pipeline capable of categorizing mutations and generating a report for discussion in a multidisciplinary precision medicine tumor board and clinical follow-up to determine the clinical impact of mutations on subsequent response to therapies and patient outcomes. The overarching goals of our trial are to understand how WES affects therapeutic decision making in the context of advanced cancer care and to identify novel biomarkers of response.

5 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BRBrian D. Robinson
Brian D. Robinson
PVPanagiotis Vlachostergios
Panagiotis Vlachostergios
BBBhavneet Bhinder
Bhavneet Bhinder
WLWeisi Liu
Weisi Liu
KLKailyn Li
Kailyn Li
BFBishoy M. Faltas
Bishoy M. Faltas
Upper tract urothelial carcinoma (UTUC) is characterized by a distinctly aggressive clinical phenotype. To define the biological features driving this phenotype, we performed an integrated analysis of whole-exome and RNA sequencing of UTUC. Here we report several key insights from our molecular dissection of this disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has a T-cell depleted immune contexture; 3) High FGFR3 expression is enriched in UTUC and correlates with its T-cell depleted immune microenvironment; 4) Sporadic UTUC is characterized by a lower total mutational burden than urothelial carcinoma of the bladder. Our findings lay the foundation for a deeper understanding of UTUC biology and provide a rationale for the development of UTUC-specific treatment strategies.

31 March 2020 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
JMJoshua J. Meeks
Joshua J. Meeks
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
BFBishoy M. Faltas
Bishoy M. Faltas
JIJohn Taylor III
John Taylor III
TFThomas W. Flaig
Thomas W. Flaig
LDLars Dyrskjøt
Lars Dyrskjøt

1 September 2015 in European Urology
Verified
Journal Article
Closed access
DNDaniel P. Nguyen
Daniel P. Nguyen
BABashir Al Hussein Al Awamlh
Bashir Al Hussein Al Awamlh
XWXian Wu
Xian Wu
POPadraic O’mAlley
Padraic O’mAlley
IIIgor M. Inoyatov
Igor M. Inoyatov
DSDouglas S. Scherr
Douglas S. Scherr